Abstract
Background and objective
Stable chronic obstructive pulmonary disease (COPD) is associated with low-grade systemic inflammation as demonstrated by an increase in blood leukocytes, acute-phase proteins such as C-reactive protein, and inflammatory cytokines. Mean platelet volume (MPV) is one of the platelet (PLT) function indexes. It reflects the PLT production rate and stimulation. The changes in MPV during an exacerbation of COPD versus stable COPD have not been clearly examined. The aim of the present study was to evaluate MPV in participants during their stable phase and during an exacerbation of COPD.
Patients and methods
This study included a total of 80 COPD patients: group A included 40 patients in the stable state and group B included the remaining 40 who were admitted for exacerbation of COPD, who were followed-up for 6 weeks after recovery, and were matched with 40 healthy, nonsmoking controls. All patients underwent spirometry, laboratory investigations with respect to complete blood count, PLT count and MPV, and echocardiography.
Results
MPV revealed a highly significant decrease within the exacerbated patient group than stable ones who had lower levels of MPV than the control volunteers. There was a highly significant increase in MPV during the stable follow-up visit than during exacerbation for the same included group of patients. There was a significant positive correlation between MPV and grade of severity of COPD; 60% of the stable COPD patients were found to have pulmonary arterial hypertension by echocardiography. There was a significantly higher MPV among patients with pulmonary hypertension (PH) than those without PH. Although PLT count increased with increased severity of PH, it did not reach significance, and there was a significant increase in MPV with increased severity of PH.
Conclusion
MPV is a quick and reliable tool for the assessment of inflammatory response. PLT activation is an important prothrombotic manifestation of COPD, which may be a useful therapeutic target.
Article PDF
Similar content being viewed by others
References
Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). Definition: Chapter 1. 2010. pp. 1–7.
Vernooy H, Küçükaycan M, Jacobs A. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 2002; 166:1218–1224.
Islam M, Amin R. Total count of white blood cells in adult male smokers. J Bangladesh Soc Physiol 2007; 2:49–53.
Kume A, Kume T, Masuda K. Dose-dependent effect of cigarette smoke on blood biomarkers in healthy volunteers: observations from smoking and non-smoking. J Health Sci 2009; 55:259–264.
Green R, Rodgman A. The tobacco chemists’ research conference: a half century forum for advances in analytical methodology of tobacco and its products. Recent Adv Tob Sci 1996; 22:131–304.
Sin D, Wu L, Man S. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005; 127:1952–1959.
Torre G, Kikkert R, Aarden A. Effects of smoking on the ex vivo cytokine production. J Periodont Res 2009; 44:28–34.
Alersandri C, Basilli S, Violi F. Hypercoagulability state in patients with chronic obstructive pulmonary disease. Thromb Hemost 1994; 72:343–346.
Rostango C, Prisco D, Boddi S. Evidence for local platelet activation in pulmonary vessels in patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease. Eur Respir J 1991; 4:147–151.
Guzman A, Nieto N, Torres Y. Increased platelet and erythrocyte arginase activity in chronic obstructive pulmonary disease associated with tobacco or wood smoke exposure. J Investig Med 2011; 59:587–592.
Ferroni P, Basili S, Martini F. Soluble P-selectin as a marker of platelet hyperactivity in patients with chronic obstructive pulmonary disease. J Investig Med 2000; 48:21–27.
Hurst J, Donaldson G, Perera R. Utility of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174:867–874.
Park Y, Schoene N, Harris W. Mean platelet volume as an indicator of platelet activation: methodological issues. Hematology 2002; 13:301–306.
Gasparyan A, Sandoo A, Stavropoulos S. Mean platelet volume in patients with rheumatoid arthritis: the effect of anti-TNF-alpha therapy. Rheumatol Int 2010; 30:1125–1129.
Chu S, Becker R, Berger P. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and metaanalysis. J Thromb Haemost 2010; 8:148–156.
Braekkan K, Mathiesen B, Njolstad I. Mean platelet volume is a risk factor for venous thromboembolism: the Tromso Study, Tromso, Norway. J Thromb Haemost 2010; 8:157–162.
Shen D, Wang Y. Effects of hypoxia on platelet activation in pilots. Aviat Space Environ Med 1994; 11:191–196.
Briggs C. Quality counts: new parameters in blood cell counting. Int J Lab Hematol 2009; 31:277–297.
Sandhaus L, Meyer P. How useful are CBC and reticulocyte reports to clinicians? Am J Clin Pathol 2002; 118:787–793.
Celli B, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932–946.
Rodriguez R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117:398S–401S.
Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). Manage exacerbations: Chapter 5 (Component 4). 2010. pp. 64–90.
Miller M, Hankinson J, Brusasco V. ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J 2005; 26:319–338.
Quanjer P, Tammeling J, Cotes J. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993; 6:5–40.
Chemla V, Castelain M, Humbert J. New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure. Chest 2004; 126:1313–1317.
Gonzalez M, Ares J, Ayuela L. Combined use of pulsed and color M-mode Doppler echocardiography for the estimation of pulmonary capillary wedge pressure: an empirical approach based on an analytical relation. J Am Coll Cardiol 1999; 34:515–523.
Quiñones M, Otto M, Stoddard A. Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. Recommendations for quantification of Doppler echocardiography. J Am Soc Echocardiogr 2002; 34:167–184.
Agustí G, Noguera A, Sauleda J. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21:347–360.
Gan W, Man S, Senthilselvan A. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta analysis. Thorax 2004; 59:574–580.
Wouters F, Groenewegen H, Dentener M. Systemic inflammation in chronic obstructive pulmonary disease: the role of exacerbations. Proc Am Thorac Soc 2007; 4:626–634.
Christie D, Kottke-Marchant K, Gorman T. Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy. Platelets 2008; 19:104–110.
Dentener M, Creutzberg E, Schols A. Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax 2001; 56:721–726.
Bath P, Butterworth R. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 1996; 7:157–161
Gasparyan A, Ayvazyan L, Mikhailidis D. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des 2011; 17:47–58.
Thompson C, Eaton K, Princiotta S. Size dependent platelet subpopulations: relationship of platelet volume to ultrastructure, enzymatic activity and function. Br J Haematol 1982; 50:509–519
Freedman D, Flanders W, Gates L. Cigarette smoking and leukocyte subpopulation in men. Ann Epidemol 1996; 6:299–306.
Muhammad A, Sajjad K, Zubaida U. Effect of cigarette smoking based on hematological parameters: comparison between male smokers and nonsmokers. Turk J Biochem 2013; 38:75–80
Calapai G, Caputi A, Mannucci C. Cardiovascular biomarkers in groups of established smokers after a decade of smoking. Basic Clin Pharmacol Toxicol 2009; 104:322–328.
Loimaala A, Rontu R, Vuori I. Blood leukocyte count is a risk factor for intima-media thickening and subclinical carotid atherosclerosis in middleaged men. Atherosclerosis 2006; 188:363–369.
Ravala M, Paula A. Cerebral venous thrombosis and venous infarction: case report of a rare initial presentation of smoker’s polycythemia. Case Rep Neurol 2010; 2:150–156.
Butkiewicz A, Kemona-Chetnik I, Dymicka-Piekarska V Does smoking affect thrombocytopoiesis and platelet activation in women and men? Adv Med Sci 2006; 51:123–126.
Arslan E, Yakar T, Yavasoglu I. The effect of smoking on mean platelet volume and lipid profile in young male subjects. Anadolu Kardiyol Derg 2008; 8:422–425.
Varol E, Icli A, Kocyigit S. Effect of smoking cessation on mean platelet volume. Clin Appl Thromb Hemost 2013; 19:315–319.
Caponnetto P, Russo C, Di Maria A. Circulating endothelial coagulative activation markers after smoking cessation: a 12-month observational study. Eur J Clin Invest 2011; 4:616–626.
Bansal R, Gupta H, Goel A. Association of increased platelet volume in patients of chronic obstructive pulmonary disease: clinical implications. J Indian Acad Clin Med 2002; 3:169–172.
Onder I, Topcu S, Dokmetas HS. Platelet aggregation size and volume in chronic obstructive pulmonary disease. Mater Med Pol 1997; 29:11–13.
Biljak V, Pancirov D, Cepelak I. Platelet count, mean platelet volume and smoking status in stable chronic obstructive pulmonary disease. Platelets 2011; 22:466–470.
Ulasli SS, Ozyurek BA, Yilmaz EB, Ulubay G. Mean platelet volume as an inflammatory marker in acute exacerbation of chronic obstructive pulmonary disease. Pol Arch Med Wewn 2012; 122:122–126.
John D, David A, Shonna J. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax 2011; 10:210–215
Barbera JA, Blanco I. Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management. Drugs 2009; 69:1153–1171.
Fazli M, Nadeem K, Muhammad A. Echocardiographic findings in chronic obstructive pulmonary disease (COPD) patients. Cardiol Clin 2004; 22:383–399.
Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008; 32:1371–1385.
Chatila W, Thomashow B, Minai O. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac soc. 2008; 5:549–555.
Naeiji R. Pulmonary hypertension and corpulmonale in COPD patients. Proc Am thorac soc 2005; 2:20–22.
Sertogullarindan B, Gumrukcuoglu A, Sezgi C. Frequency of pulmonary hypertension in patients with COPD due to bio-mass smoke and tobacco smoke. Int J Med Sci 2012; 9:406–412.
Andersen K, Iversen M, Kjaergaard J. Prevalence, predictors and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. J Heart Lung Transplant 2012; 31:373–380.
Gajanan k. Retrospective study of frequency of pulmonary hypertension in chronic obstructive pulmonary disease (COPD). Med Sci 2014; 12:2249–2255.
Simonneau G, Robbins I, Beghetti M. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54:S43–S54.
Berger G, Azzam Z, Hoffmann R. Coagulation and anticoagulation in pulmonary arterial hypertension. Isr Med Assoc J 2009; 11:376–379.
Chaouat A, Weitzenblum E, Higenbottam T. The role of thrombosis in severe pulmonary hypertension. Eur Respir J 1996; 9:356–363.
Tolga S, Hatice B, Sami I. Comparison of meanplatelet volume values among different causes of pulmonary hypertension. Cardiol J 2012; 19:180–187.
Can M, Tanboga H, Demircan C. Enhanced hemostatic indices in patients with pulmonary arterial hypertension: an observational study. Thromb Res 2010; 126:280–282.
Perros F, Montani D, Dorfmüller P. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178:81–88.
Mustafa S, Onder O, Mehmet F. Platelet indices in patients with pulmonary arterial hypertension. Clin Appl Thromb Hemost 2011; 17:171–174.
Derya A, Osman G, Fatma K. Platelet distribution width and mean platelet volume in children with pulmonary arterial hypertension secondary to congenital heart disease with left-to-right shunt: new indices of severity? Pediatr Cardiol 2013; 34:1013–1016.
Peinado V, Pizarro S, Barberà J. Pulmonary vascular involvement in COPD. Chest 2008; 134:808–814.
Alper A, Akyol A, Hasdemir H. Effect of cardiac resynchronization therapy on mean platelet volume. Acta Cardiol 2008; 63:735–739.
Author information
Authors and Affiliations
Corresponding author
Additional information
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Ali, E.R. Role of mean platelet volume in patients with chronic obstructive pulmonary disease. Egypt J Bronchol 10, 251–260 (2016). https://doi.org/10.4103/1687-8426.193635
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.4103/1687-8426.193635